Literature DB >> 32490102

Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid.

Brent Folsom1, Tom Raisanen2, Milad Eshaq2.   

Abstract

Entities:  

Keywords:  BP, bullous pemphigoid; BP180; BP230; CBC, complete blood count; WBC, white blood cell count; acral; blisters; bullous; bullous pemphigoid; dapsone; eosinophilia; infant; infantile; intravenous immunoglobulin; salt-split skin; spongiosis

Year:  2020        PMID: 32490102      PMCID: PMC7256229          DOI: 10.1016/j.jdcr.2020.04.006

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN: 2352-5126


× No keyword cloud information.

Introduction

Bullous pemphigoid (BP) is a rare autoimmune bullous disorder caused by IgG autoantibodies against hemidesmosomes at the dermoepidermal junction. BP typically occurs in elderly patients but is rarely reported in infants and children. In infants, associations with infection and vaccinations have been proposed., Topical and systemic steroids are considered first-line treatment options. Disease severity and clinical course vary significantly between patients, and steroid-sparing medications may be necessary.,

Case 1

A 4-month-old boy with a history of eczema and no vaccinations in the previous 2 months presented with a 25-day history of a pruritic blistering rash. The rash started on the hands and feet and then spread to the back. Physical examination found erythematous, polycyclic papules and plaques on the hands, feet, and back (Fig 1) with no mucosal involvement. There were numerous tense bullae filled with serous fluid on the dorsal and ventral surfaces of the hands and feet (Fig 2).
Fig 1

Case 1. Erythematous and edematous polycyclic plaques distributed over the back.

Fig 2

Case 1. Tense bullae containing serous fluid on the hand.

Case 1. Erythematous and edematous polycyclic plaques distributed over the back. Case 1. Tense bullae containing serous fluid on the hand. Punch biopsy from the abdomen for hematoxylin and eosin found eosinophilic spongiosis, superficial perivascular inflammation, and numerous eosinophils within the papillary tips. A perilesional punch biopsy for direct immunofluorescence showed linear IgG and C3 along the dermoepidermal junction. Enzyme-linked immunosorbent assay of the patient's serum showed BP180 IgG antibody (BP180) greater than 150 U (normal <9) and normal BP230 IgG antibody (BP230) (normal <9). Additionally, indirect immunofluorescence testing of the patient's serum on human salt-split skin substrate showed IgG antibodies along the basement membrane in an epidermal staining pattern. The patient was treated with 3 days of intravenous methylprednisolone and then transitioned to oral prednisone, 1 mg/kg/d. No new blisters were observed at 3-week follow-up, and he tapered off prednisone over 14 weeks. The patient remained free of disease at 9 months.

Case 2

A 2-month-old healthy girl presented with a widespread blistering rash that began on her feet the day after her 2-month vaccinations (DTap, Hib, Rotavirus [RV5], PCV13, and Polio [IPV]). On examination, she had erythematous, edematous, polycyclic plaques distributed over the face, trunk, extremities, hands, and feet (Fig 3), including involvement of both the dorsal and ventral surfaces of the hands and feet. There were numerous overlying tense and ruptured bullae (Fig 4). No mucosal lesions were observed.
Fig 3

Case 2. Scattered tense bullae within a widespread annular rash on the leg.

Fig 4

Case 2. Ruptured bullae over a bed of erythematous, edematous, polycyclic plaques on the lower leg and foot.

Case 2. Scattered tense bullae within a widespread annular rash on the leg. Case 2. Ruptured bullae over a bed of erythematous, edematous, polycyclic plaques on the lower leg and foot. Skin biopsy for hematoxylin-eosin stain found eosinophilic and neutrophilic spongiosis with small clusters of neutrophils in the papillary dermal tips. Perilesional biopsy for direct immunofluorescence showed linear IgG and C3 along the dermoepidermal junction and weak linear IgA. Serum enzyme-linked immunosorbent assay showed BP180 greater than 100 U and normal BP230. Indirect immunofluorescence performed with the patient's serum showed basement membrane zone IgG antibodies in an epidermal pattern on human salt-split skin substrate. Complete blood count (CBC) was notable for white blood cell (WBC) count of 27.8 K/μL (normal, 6-18 K/μL), platelets of 1,022 K/μL (normal, 150-400 K/μL), and absolute eosinophil count of 4.6 K/μL (normal, 0-0.9 K/μL). She was treated with intravenous methylprednisolone for 3 days followed by oral prednisolone titrated up to 2 mg/kg/d. Given ongoing new lesions, oral erythromycin, 50 mg/kg/d, and niacinamide, 40 mg 3 times daily were added. Three weeks after treatment started, she still had widespread, active disease, so dapsone was added at 0.5 mg/kg/d and titrated up to 1.5 mg/kg/d. The patient continued to have active cutaneous disease, and laboratory values still showed elevated WBCs and platelets with absolute eosinophils increasing to 7.34 K/μL. Three weeks after initiation of dapsone, the patient began to improve. Within days of obtaining disease control, her absolute eosinophil count normalized to 0.01 K/μL with decreases in her WBC and platelet counts. Erythromycin and niacinamide were discontinued. A steroid taper was initiated 3 months later, and a dapsone taper began after another month. A mild flare occurred with an upper respiratory infection, so dapsone was increased back to its prior dose, and erythromycin and niacinamide were restarted. She successfully tapered off systemic steroids while being monitored for adrenal insufficiency 6 months after initial presentation.

Discussion

The inciting factors of infantile BP are not fully understood, but stimulation of the immune system by vaccination has been proposed as a trigger., As the presented cases and previous literature demonstrate, a history of recent vaccination is not universal, and the time from vaccination to disease manifestation varies greatly. In one study, the clinical characteristics of 81 infantile BP patients were analyzed, and it was determined 25 patients (30.8%) recently received vaccinations with recent being defined as within the previous 4 weeks. The number and type of vaccines received varied among patients. In case 2, the patient received vaccinations 1 day before her rash started, which suggests the vaccines may have been a trigger. The presented cases of infantile BP show common clinical and laboratory features of the disease. Both manifested as a blistering rash on acral skin surfaces followed by widespread skin involvement sparing the mucosae. Infantile BP has near-universal involvement of acral sites often followed by a generalized spread and infrequent mucosal involvmement. The elevated BP180 levels with normal BP230 levels in both cases is representative of infantile BP, which manifests with elevation of BP180 and rarely BP230.,, The patient in case 2 showed prominent and persistent eosinophilia on her CBC that only decreased once she stopped getting new skin lesions. Previous case reports similarly show eosinophilia on CBC, suggesting eosinophil counts as a possible marker for disease activity and treatment response. These cases show differing responses to initial corticosteroid treatment. The patient in case 1 responded quickly, whereas the patient in case 2 required a longer course of corticosteroids and additional steroid-sparing agents. Most infantile BP cases respond quickly to systemic corticosteroids, but dapsone is often given with systemic corticosteroids in refractory cases.,, intravenous immunoglobulin may also be considered in infantile BP treatment, especially in recalcitrant disease.,, Although infantile BP is considered a rare disease, its incidence has been growing. Whether this is caused by increased disease incidence or better diagnostic techniques is uncertain, but clearly defined diagnostic and treatment guidelines would aid clinicians in identifying and treating patients.
  10 in total

1.  Childhood bullous pemphigoid developed after the first vaccination.

Authors:  C Baykal; G Okan; R Sarica
Journal:  J Am Acad Dermatol       Date:  2001-02       Impact factor: 11.527

Review 2.  Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review.

Authors:  Sonia de la Fuente; Ángela Hernández-Martín; Raúl de Lucas; Ma Antonia González-Enseñat; Asunción Vicente; Isabel Colmenero; María González-Beato; Mariona Suñol; Antonio Torrelo
Journal:  Pediatr Dermatol       Date:  2013-10-11       Impact factor: 1.588

Review 3.  Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.

Authors:  Burak Tekin; Ayşe Deniz Yücelten
Journal:  Pediatr Dermatol       Date:  2015-06-29       Impact factor: 1.588

4.  Infantile bullous pemphigoid successfully treated with intravenous immunoglobulin therapy.

Authors:  T Watanabe; S Hara; J Muto; D Watanabe; M Akiyama
Journal:  Clin Exp Dermatol       Date:  2017-05-22       Impact factor: 3.470

Review 5.  Bullous pemphigoid of infancy - report and review of infantile and pediatric bullous pemphigoid.

Authors:  Bárbara R Ferreira; Ana S Vaz; Leonor Ramos; José P Reis; Margarida Gonçalo
Journal:  Dermatol Online J       Date:  2017-02-16

Review 6.  Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy.

Authors:  Nobuyuki Sugawara; Yayoi Nagai; Yoichiro Matsushima; Kumi Aoyama; Osamu Ishikawa
Journal:  J Am Acad Dermatol       Date:  2007-09-24       Impact factor: 11.527

Review 7.  Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics.

Authors:  Orith Waisbourd-Zinman; Dani Ben-Amitai; Arnon D Cohen; Meora Feinmesser; Daniel Mimouni; Ayelet Adir-Shani; Marina Zlotkin; Alex Zvulunov
Journal:  J Am Acad Dermatol       Date:  2007-10-22       Impact factor: 11.527

8.  Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.

Authors:  Luca Baroero; Paola Coppo; Laura Bertolino; Stefano Maccario; Francesco Savino
Journal:  BMC Pediatr       Date:  2017-02-23       Impact factor: 2.125

9.  Severe Infantile Bullous Pemphigoid Treated with Dapsone after Bridging with Systemic Glucocorticoid.

Authors:  Kenneth Thomsen; Mette Deleuran; Christian Vestergaard; Mette Holm; Rikke Riber-Hansen; Rikke Bech
Journal:  Case Rep Dermatol       Date:  2019-06-26

10.  Bullous pemphigoid in infants: characteristics, diagnosis and treatment.

Authors:  Agnes Schwieger-Briel; Cornelia Moellmann; Birgit Mattulat; Franziska Schauer; Dimitra Kiritsi; Enno Schmidt; Cassian Sitaru; Hagen Ott; Johannes S Kern
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.